(Applicant's narrative) The Southwest Oncology Group has evolved since its inception in 1956 into an adult multi-disease, multi-modality clinical research organization. This organization has grown to include 34 Full Member Institutions, 23 Community Clinical Oncology Program (CCOP) institutions, including four Minority-Based CCOPs, 30 Urologic Cancer Outreach Program (UCOP) members, 26 High Priority program members and a network of approximately 927 Cooperative Group outreach Program (CGOP) investigators at 306 affiliate hospitals. In addition, 17 Group institutions also participate in the CTEP Minority Initiative program, which serves to enhance minority accrual in cancer clinical trials. More than 4,000 investigators, representing all research modalities, are members of the Group and actively participate in the registration of patients to cancer treatment and cancer control and prevention protocols. In addition, the Southwest Oncology Group coordinates the large intergroup chemoprevention trial funded by DCPC, the Prostate Cancer Prevention Trial (PCPT). Two hundred and thirty-two PCPT institutional sites affiliated with the Southwest Oncology Group and two other cooperative groups participate in this trial. The Southwest Oncology Group is also committed to representative accrual of women and minority patients and subjects to Group clinical trials. To this end, the Group has developed an extremely active Committee on Women's Health, which serves to evaluate and enhance the accrual of women to Group trials, identify and address special concerns regarding women's health issues in the cooperative group setting, and act as a direct liaison with women's health groups, such as the Office of Research on Women's Health (ORWH). In addition, minority accrual has been enhanced by the participation of the Minority-based CCOPs and other minority institutions, the Minority Research Subcommittee of the Cancer Control Research Committee, and numerous PCPT minority recruitment enhancement activities sponsored by the NCI and the Group. A new Group initiative involves the exploration of the role and feasibility of patient advocates and patient representatives under development include the utilization of patient advocate representatives in the development of proposed breast and lung cancer clinical trials, and possible distribution of Southwest Oncology Group clinical trials information materials to """"""""hot lines"""""""" sponsored by patient advocate groups for dissemination upon request by callers. The Southwest Oncology Group has continued to pursue the goals of the National Cancer Institute CCOP program through innovative membership, and unsurpassed excellence in patient accrual and quality-controlled research data from the CCOP affiliates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037429-15S4
Application #
6156384
Study Section
Special Emphasis Panel (SRC (15))
Project Start
1983-09-30
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
15
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Cancer Therapy and Research Center
Department
Type
DUNS #
010550366
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Cook, Michael B; Barnett, Matthew J; Bock, Cathryn H et al. (2018) Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. Gut :
Hershman, Dawn L; Unger, Joseph M; Greenlee, Heather et al. (2018) Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 320:167-176
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Zhang, X; Schmitt, F A; Caban-Holt, A M et al. (2017) Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. J Prev Alzheimers Dis 4:143-148
Ng, Maggie C Y; Graff, Mariaelisa; Lu, Yingchang et al. (2017) Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. PLoS Genet 13:e1006719
Lance, Peter; Alberts, David S; Thompson, Patricia A et al. (2017) Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila) 10:45-54
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:

Showing the most recent 10 out of 368 publications